Bevacizumab (Avastin, Genentech/Roche), one of the first clinically-approved angiogenesis inhibitors, has been used to treat patients with metastatic colorectal, lung, renal, and ovarian cancers by blocking the vascular endothelial growth factor (VEGF) pathway [6]. This evidence concerns the gene VEGFA and ovarian carcinoma.